Member Info for Davemcmanus

Sang I don't think 0518 is a million years away from approval, equally i know it's not going to happening in months. It is about three years away when you factor in the Accelerated approval study, and FDA review timelines.

Hopeingmore no they don't, check again. As Sang says all shares held by retail investors will have their broker's such HL listed as the owner. You din't technically own the shares, they are owned by the Broker. You have the right to trade the security. How do you think they loan shares to the shorters?

Sharcus they hold less than 10% combined, not sure how you class this to be a major II holding lol.

You'd have to be an idiot to trust what Trickymatters AKA Sharon hunter says. She went from ramping GDR to ramping ODX after the placing, now back at GDR. She is evil person trading the shares, whilst giving the gullible wild projections. Just look at her posts previously both on ODX and here previously. Oh and her imaginary £25k "topups" lol

"IIs ownership is significant enough to be able to affect any kind of a vote. Plus, insiders do own a decent chunk."

Phil you're really making stuff up to make yourself feel better, not wanting to be rude. IIS and institutions only own just over 20% of the business, how do they own enough to affect a vote? You can't even tell us who these alleged institutional investorsare, as i'm sure 90% of other posters would like to know. The majority of shares are in retail hands. Also bear in mind this speculative stock, Institutions are not in the business of holding for multi baggers. They sell at a profit, as you've seen with Acacia both here and SNG. They have a strict risk profile they stick to, and those buying now won't bat eyelid for selling x6 the current price.

Again with regards to Duncan it all depends on what is in offer on the table for him at the time, as well as the financial state of the company. He can have the best results he wants, but if he has no institutional backing to provide cash in order to fund his "big pipeline", his only option will be to raise cash at a very low price and dilute the shares to hell, or get a TO from a big pharma that has financial resource to provide funding for 4D until it becomes commercial. It's not rocket science which option they would take in these circumstances. Their big investment makes no difference if they can't get the cash they need and to develop the pipeline. I am sure they had high hopes for NASDAQ but that too has been a failure too date.

Phil are you having a laugh right?

1. Your first point sbout institutional investment is a load of BS, is because there aren't any. Name the institutions hold big stakes here. If you had seriously researched the company, you would have known this share is predominantly retail hence it's volatility.

2. Again there aren't any institutions with a significant stake to mske a difference. The majority of the retail investors would vote it through. You can't say a pipeline is worth billions until it's proven. There is no guarantee MRX0518 will be successful in all at this early stage, so pipe down with your £100bn projections. We are a few years away before we even know if it will be a success. You are commenting as if there will be a 100% success rate. Also you haven't answred thd question on what you expect the SP to be on successful results.

3. Do you honestly believe Duncan gives a toss about retail investors he has never met lol. You're deluded. Duncan's will be acting in his own best interests, so it all depends on what's on the table for him on the other side. Salary, managements options in big pharma etc....

Furthermore if Duncan cannot get Institutions on board, he will have no option to accept a TO. How else do you think "big pipeline" you talk about will be funded? Retail investors like you and cannot keep this company afloat, it's a capital hungry biotech, that's where the institutions come in. Why do you think they went to NASDAQ? Certainly wasn't because they bored one day and decided to try something new. They had hoped to get US institutions on board after failing to get any in the UK, but it didn't work out as planned.

"Those who think 4D should go for £3 /share really need to do some DD and find out what they hold. This is either going to flop completely if miraculously microbiome proves to be a dud"

Phil I guess you're comment is aimed at me after i suggested £3 a share. As i said the other day it may be worth billions one day, BUT it won't be the current investors that reap the rewards of a multi billion dollar company. It will get bought out long before then for anything between £1-£2bn. Factor in the dilution that needs is yet to come to get it to that stage, you're talking a maximum buyout of around £5- £7 a share. Therefore given the choice of taking £3 now and investing elsewhere, or hold for another 3-5 years and potentially getting £7 a share or seeing it turn to a dud, the smart money will sell at £3 a run. At that point risk starts to outweigh reward, with only a 100% upside. I think it's you that needs to research what pharmas typically sell for, or you must be from that crazy Telegram group expecting £40 a share. What are your expectations on good phase 3 results?

"However, what is not on is the LACK of a PROGRESS REPORT on 0518 and the lack of an explanation re the reasons for the delays (even without revealing sensitive data)."

Totally agree with this. However one think i'd like to point out is the fact this is an open label trial, so there isn't any sensitive information, and there drip fed updates to the market throughout the year. Instead they've witheld the information without a reasnoable explanation, and missed every guidance they gave on it.

"Fundamentals in my opinion have never looked better. Things progressing on all fronts (including Blautix!)."

Phil everything progressing apart from the SP, the NASDAQ interest, or any institutional investmrnt which will drivd valye.No point if things are progressing but the dilution keeps getting bigger and bigger, because they are forced to raise at low SPs. Duncan should have addressed this by the end of the year, instead he's done SFA and done a disastorous 4 minute interview straight out of bed. He's got alot of work to do for Q1 before investors lose total confidence in this company.

"The money that comes after DDDD /if/ they get something over the line will dwarf by a long way what "regular Joes" have put in here. I doubt anyone needs or relies on "regular Joes"."

Bucklefurn if you didn't aready know, the majority of shareholders here are "regular joes" , so yes it's impirtant for the company to keep us informed. A low shareprice puts the company into financial risk, as they may not be able to raise much needed funds or they raise so low the SP gets diluted to oblivion. So no it's not all about the science and future potential, the SP and shareholder relationship are very important.

Agree with all that's been said here regarding the presentation. Just like previous ones it was appalling, no enthusiasm or talking up the company and it's prospects. It's almost as if he was forced to be there. Is it therefore a surprise why this company is so undervalued, and lacks any institutional support? He's having a hard time convincing retail to invest here, what chance does he stand with the funds? Still no PR or liquidity on NASDAQ or interest from US investors, so something wrong somewhere.

How does any company get institutions on board Sang? That's what they pay their brokers and PR company for.

Get some proper investors on board for a start. All this talk about NASDAQ before listing, but what have they achieved there? No makes no difference to you Sang, you're only in it fir your quick 10%s

If it stays at 50-60 in Q1, then management will look like prats considering last placing was at 1.10. They need to start focussing on the shareprice.

Coldbrew i guess there are two sides to every store. Whilst the BOD may not accept a low iffer from the likes of Merck, they would keep a lid on the SP if they were planning a Management buyout. It does seem strange we've had no broker coverage since NASDAQ, or any PR across the pond.

Merck offered this lot $65m which was politely refused, thrn bought them out gor $1.9bn just months later.

https://www.fiercebiotech.com/biotech/pandion-s-secret-to-moving-a-65m-merck-offer-to-a-1-9b-done-deal-a-year-just-keep-saying-no

"Clinigen got bought out last week at a 50% premium only - yet people seem to think a Merck buyout would be £3+ a share.That seems completely unrealistic to me. A buyout around £1 a share"

ColdBrew that's a load of nonsense, firstly because Merck took part on the placing at £1.10, so tgey cannot make a takeover off less than for 12 months. Secondly there are placees in at higher levels who will want a return on the investment, and don't forget fair value is £3 where the company stands right now. The BOD are not stupid to give it away for free, even though thrir primary interests would lie what was on the table for them on the other side. They wouldn't have taken out the loan facility of they were looking to sell for £1. Just because a low offer comes in doesn't mean to say it has to be expected. Equally people need to keep their feet firmly on the ground and not get carried away with takeover offer expectations right now. £3 will be a nice exit even for the BOD.

"We’ve also got a couple firms shorting us. Ones prospectus stated they targeted firms with high PI interest with unrealistic expectations. "

They've probably been on Rog and Lee's Telefram group, where people are not selling for less thsn £40 a share lol

Boonco it won't take is much to get to £3 a share or £500m mcap, as we need this just to catchup with our peers. However to even bag again from those levels will need serious results, which will take years not months. If given the option to take £3 now or POTENTIALLY £5-£8 in 3-5 years which is realistically going to the top end of any buyout taking into account any further dilution, then taking the cash now is a no brainer. You say dilution is not a bad thing, but pre Blautix we were trading at £1.80 or £232m mcap, today that is equal to £1.28. If we went back up to £232m tommorow all LTHs will be a wopping 52p a share worst off than last year, regardless of the fact of their entry was lower than the £1.10 placing. You need to take this into account, rather than looking at a larger mcap upon sale. It doesn't make sense if you're going to end up less per share, regardless of higher price in 3-5 years.
Also is it really worth holding another 5 years for an extra 100% or so gain?? You also have to factor in the risks of holding (sector crash, market sentiment, bad trial results) all of which we have seen this year, plus the opportunity cost of cash tied up.
If you take your gains elsewhere and compound 50-100% every year, it leaves your pot much higher than any potential exit at 4D anyway. This is't going to hit the crazy highs like some of you believe, it will get taken out way before then. As has already been said many times the current investors will never see the full upside of this, as the likes of Merck will have ling taken it out whilst it's cheap.

Agree Porky don't see £3 a share in the medium being turned down by many, it's realistic, achievable and sensible. Much rather take the cash and move on, life is too short to be fretting about one share. There are some delusionisit though expecting £40+ a share lol...